Biofidelity is developing liquid biopsy PCR technology for the detection of small amounts of circulating tumour DNA in a blood sample.

With a limit of detection 10-50 times lower than the current FDA-approved methods, the Company can identify known mutations whose presence or absence can guide clinical decisions. Sensitive liquid biopsy techniques hold great promise as companion diagnostics for the accurate diagnosis and treatment of cancers, allowing regular, non-invasive monitoring of patients. Biofidelity was spun out from Cambridge-based parent company Base4 Innovation in 2Q 2019 to commercialise the technology initially developed for DNA sequencing applications.

Visit website